IP Library › Granted Patent US 9,139,835
Granted Patent B2
US 9,139,835 · App. 13/964,904 · Granted Sep 22, 2015

Nucleic acid aptamers

Inventors: Paloma Giangrande (Iowa City, IA); Francis Miller (Iowa City, IA); William Thiel (Iowa City, IA)
Assignee: University of Iowa Research Foundation
C12N15/115C12N15/1048C12N15/1137C12N2310/14C12N2310/16C12N2310/3519C12N2320/32C12Y106/03001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,139,835
App. No.
13/964,904
Granted
Sep 22, 2015
Kind
B2
Abstract

The present invention relates to optimized aptamers and methods of using these aptamers.

Claims (15)

1. A nucleic acid molecule not more than 90 nucleotides in length comprising an aptamer, wherein the aptamer is aptamer-51 (SEQ ID NO:2373), aptamer-13 (SEQ ID NO:2335), aptamer-14 (SEQ ID NO:2336), aptamer-8 (SEQ ID NO:2330), aptamer-5 (SEQ ID NO:2327), aptamer-3 (SEQ ID NO:2325), aptamer-35 (SEQ ID NO:2366), aptamer-6 (SEQ ID NO:2328), or aptamer-11 (SEQ ID NO:2333).

2. The nucleic acid molecule of claim 1 , wherein the aptamer is aptamer-14 (SEQ ID NO:2336), or aptamer-51 (SEQ ID NO:2373).

3. The nucleic acid molecule of claim 1 , wherein the nucleotides are RNA.

4. The nucleic acid molecule of claim 3 , wherein the RNA includes a modified nucleotide.

5. The nucleic acid molecule of claim 4 , wherein the RNA is chemically modified (2′-fluoropyridines).

6. A conjugate comprising the nucleic acid molecule of claim 1 linked to a therapeutic or diagnostic molecule.

7. The conjugate of claim 6 , wherein the therapeutic molecule is an RNAi molecule.

8. The conjugate of claim 7 , wherein the RNAi molecule is an siRNA molecule or an miRNA molecule.

9. The conjugate of claim 8 , wherein the siRNA specifically targets N×1 NADPH oxidase.

10. A method for delivering a therapeutic or diagnostic molecule to a vascular smooth muscle cell, comprising contacting the cell with the conjugate of claim 6 .

11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and

(i) a nucleic acid molecule not more than 90 nucleotides in length comprising an aptamer, wherein the aptamer is aptamer-51 (SEQ ID NO:2373), aptamer-13 (SEQ ID NO:2335), aptamer-14 (SEQ ID NO:2336), aptamer-8 (SEQ ID NO:2330), aptamer-5 (SEQ ID NO:2327), aptamer-3 (SEQ ID NO:2325), aptamer-35 (SEQ ID NO:2366), aptamer-6 (SEQ ID NO:2328), or aptamer-11 (SEQ ID NO:2333); or

(ii) conjugate comprising the a nucleic acid molecule not more than 90 nucleotides in length comprising an aptamer, wherein the aptamer is aptamer-51 (SEQ ID NO:2373), aptamer-13 (SEQ ID NO:2335), aptamer-14 (SEQ ID NO:2336), aptamer-8 (SEQ ID NO:2330), aptamer-5 (SEQ ID NO:2327), aptamer-2 (SEQ ID NO:2333), aptamer-3 (SEQ ID NO:2325), aptamer-35 (SEQ ID NO:2366), aptamer-6 (SEQ ID NO:2328), or aptamer-11 (SEQ ID NO:2333), linked to a therapeutic or diagnostic molecule.

12. An article of manufacture comprising a solid substrate coated with the molecule of claim 1 .

13. The article of claim 12 , wherein the solid substrate is a stent, catheter, a catheter hub, a catheter port, or a non-degradable implant.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2014
From: GIANGRANDE, PALOMA H.; MILLER, FRANCIS; THIEL, WILLIAM
To: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Reel/Frame 032022/0407 →
CONFIRMATORY LICENSE Recorded Aug 22, 2013
From: UNIVERSITY OF IOWA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031075/0414 →
Continuity (3)
Provisional Application 61682055 · Aug 10, 2012
Provisional Application 61792723 · Mar 15, 2013
Related Publication 20140056959A1 · Feb 27, 2014